Capula Management Ltd Sells 57,926 Shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)

Capula Management Ltd lowered its position in shares of Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 65.3% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 30,797 shares of the company's stock after selling 57,926 shares during the period. Capula Management Ltd's holdings in Arcutis Biotherapeutics were worth $429,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Point72 DIFC Ltd bought a new position in shares of Arcutis Biotherapeutics during the third quarter valued at about $25,000. Venturi Wealth Management LLC bought a new stake in shares of Arcutis Biotherapeutics in the 4th quarter worth approximately $46,000. Cibc World Markets Corp purchased a new position in shares of Arcutis Biotherapeutics during the fourth quarter valued at approximately $140,000. LVW Advisors LLC bought a new position in shares of Arcutis Biotherapeutics during the fourth quarter valued at approximately $166,000. Finally, Aigen Investment Management LP bought a new stake in Arcutis Biotherapeutics in the fourth quarter valued at $191,000.

Arcutis Biotherapeutics Stock Down 6.3 %

NASDAQ:ARQT traded down $0.85 during trading hours on Friday, reaching $12.59. 4,853,450 shares of the company traded hands, compared to its average volume of 2,409,191. The company has a current ratio of 2.46, a quick ratio of 2.38 and a debt-to-equity ratio of 0.67. The business's 50-day moving average price is $14.23 and its two-hundred day moving average price is $12.62. Arcutis Biotherapeutics, Inc. has a 1 year low of $6.99 and a 1 year high of $17.75. The stock has a market capitalization of $1.49 billion, a P/E ratio of -7.03 and a beta of 1.67.

Arcutis Biotherapeutics (NASDAQ:ARQT - Get Free Report) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.28) by $0.19. The company had revenue of $71.36 million for the quarter, compared to analysts' expectations of $60.52 million. Arcutis Biotherapeutics had a negative net margin of 140.97% and a negative return on equity of 119.11%. Analysts predict that Arcutis Biotherapeutics, Inc. will post -1.33 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research analysts have commented on ARQT shares. Guggenheim restated a "buy" rating on shares of Arcutis Biotherapeutics in a report on Thursday, April 3rd. The Goldman Sachs Group raised their price objective on shares of Arcutis Biotherapeutics from $13.00 to $15.00 and gave the stock a "neutral" rating in a report on Thursday, February 27th. Jefferies Financial Group increased their target price on Arcutis Biotherapeutics from $16.00 to $19.00 and gave the stock a "buy" rating in a research report on Tuesday, March 11th. Mizuho lifted their price target on Arcutis Biotherapeutics from $20.00 to $21.00 and gave the company an "outperform" rating in a research report on Wednesday, February 26th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $20.00 target price on shares of Arcutis Biotherapeutics in a research report on Wednesday. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat.com, Arcutis Biotherapeutics has an average rating of "Moderate Buy" and an average target price of $18.80.

Insider Transactions at Arcutis Biotherapeutics

In related news, insider Masaru Matsuda sold 8,338 shares of the company's stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $12.70, for a total value of $105,892.60. Following the transaction, the insider now directly owns 178,692 shares of the company's stock, valued at approximately $2,269,388.40. This represents a 4.46 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Howard G. Welgus sold 10,000 shares of Arcutis Biotherapeutics stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $12.71, for a total value of $127,100.00. Following the completion of the sale, the director now directly owns 141,944 shares of the company's stock, valued at approximately $1,804,108.24. The trade was a 6.58 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 46,099 shares of company stock worth $631,256. Corporate insiders own 9.50% of the company's stock.

Arcutis Biotherapeutics Company Profile

Arcutis Biotherapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis.